This website is for UK Healthcare Professionals only

Video library

Haematology experts provide their opinions on key topics in the treatment of AML

VIALE-A: Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Dr. Richard Dillon provides an overview of the VIALE-A trial of azacitidine and venetoclax in previously untreated acute myeloid leukemia patients who were ineligible for intensive chemotherapy

Management strategies and real-world experience with venetoclax in first-line AML

Watch Dr. Richard Dillon discuss his experience using venetoclax in clinical practice. He explains how he manages venetoclax in first-line AML

Expert opinion: Using venetoclax in first-line chemotherapy-ineligible AML

Watch Professor Nigel Russell discuss venetoclax treatment in first-line AML patients ineligible for intensive chemotherapy


Adverse events should be reported. Reporting forms and information can be found at

Adverse events should also be reported to AbbVie on [email protected]

UK-VNCAML-230083. Date of preparation: October 2023.